The Tübingen University Hospital in conjunction with its partner site Centre de Recherche Medicales Lambaréné (CERMEL) has analysed data from the first 39 participants in its Phase I Ebola vaccine trial, being conducted as part of a World Health Organisation (WHO) initiated consortium.
The study is investigating the vaccine candidate rVSV-ZEBOV-GP developed by the Canadian Public Health Agency and produced by the US firm NewLink Genetics. More recently, it has been bought by Merck, who are supporting further Phase I as well as Phase II and III trials.
In the initial phase, two doses of the vaccine were tested in 39 participants in Lambarene, Gabon. Safety, tolerability and immunogenicity of the vaccine were assessed with very promising results.
In addition, a variety of doses of the vaccine were tested at collaborating sites internationally and the data are summarised in a paper published in the New England Journal of Medicine on the 1st April.
rVSV-ZEBOV-GP is a unique vaccine which uses a replicating virus in which the coat protein, recognised by the immune system, has been replaced with a coat protein from the Ebola virus (EBOV). The study in Lambaréné has shown that a single injection of this vaccine is well tolerated and generates a good immune response to EBOV.
The study in Lambaréné, headed by Principle Investigator Dr. Maxime Agnandji and Tübingen’s Professor Peter Kremsner is currently vaccinating further adults in an attemptto establish an optimal dose, and will begin vaccinating adolescents and children later this month.
The data from this site are vital for informing further clinical trials of the vaccine, licensure proceedings and how it will eventually be deployed in West Africa.
Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe — Preliminary Report
N Engl J Med. DOI: 10.1056/NEJMoa1502924
S.T. Agnandji, A. Huttner, M.E. Zinser, P. Njuguna, C. Dahlke, J.F. Fernandes, S. Yerly, J., J-A. Dayer, V. Kraehling, R. Kasonta, A.A. Adegnika, M. Altfeld, F. Auderset, E.B. Bache, N. Biedenkopf, S. Borregaard, J.S. Brosnahan, R. Burrow, C. Combescure, J. Desmeules, M. Eickmann, S.K. Fehling, A. Finckh, A.R. Goncalves, M.P. Grobusch, J. Hooper, A. Jambrecina, A.L. Kabwende, G. Kaya, D. Kimani, B. Lell, B. Lemaître, A.W. Lohse, M. Massinga-Loembe, A. Matthey, B. Mordmüller, A. Nolting, C. Ogwang, M. Ramharter, J. Schmidt-Chanasit, S. Schmiedel, P. Silvera, F.R. Stahl, H.M. Staines, T. Strecker, H.C. Stubbe, B. Tsofa, S. Zaki, P. Fast, V. Moorthy, L. Kaiser, S. Krishna, S. Becker, M.-P. Kieny, P. Bejon, P.G. Kremsner, M.M. Addo, and C. A. Siegrist
Medizinische Klinik, Institut für Tropenmedizin
Prof. Dr. Peter G. Kremsner
Wilhelmstr. 27, 72076 Tübingen
Tel. 0049 (0)7071 29-87179
Dr. Ellen Katz | idw - Informationsdienst Wissenschaft
Study tracks inner workings of the brain with new biosensor
16.08.2018 | Rheinische Friedrich-Wilhelms-Universität Bonn
Foods of the future
15.08.2018 | Georg-August-Universität Göttingen
New design tool automatically creates nanostructure 3D-print templates for user-given colors
Scientists present work at prestigious SIGGRAPH conference
Most of the objects we see are colored by pigments, but using pigments has disadvantages: such colors can fade, industrial pigments are often toxic, and...
Scientists at the University of California, Los Angeles present new research on a curious cosmic phenomenon known as "whistlers" -- very low frequency packets...
Scientists develop first tool to use machine learning methods to compute flow around interactively designable 3D objects. Tool will be presented at this year’s prestigious SIGGRAPH conference.
When engineers or designers want to test the aerodynamic properties of the newly designed shape of a car, airplane, or other object, they would normally model...
Researchers from TU Graz and their industry partners have unveiled a world first: the prototype of a robot-controlled, high-speed combined charging system (CCS) for electric vehicles that enables series charging of cars in various parking positions.
Global demand for electric vehicles is forecast to rise sharply: by 2025, the number of new vehicle registrations is expected to reach 25 million per year....
Proteins must be folded correctly to fulfill their molecular functions in cells. Molecular assistants called chaperones help proteins exploit their inbuilt folding potential and reach the correct three-dimensional structure. Researchers at the Max Planck Institute of Biochemistry (MPIB) have demonstrated that actin, the most abundant protein in higher developed cells, does not have the inbuilt potential to fold and instead requires special assistance to fold into its active state. The chaperone TRiC uses a previously undescribed mechanism to perform actin folding. The study was recently published in the journal Cell.
Actin is the most abundant protein in highly developed cells and has diverse functions in processes like cell stabilization, cell division and muscle...
17.08.2018 | Event News
08.08.2018 | Event News
27.07.2018 | Event News
17.08.2018 | Life Sciences
17.08.2018 | Event News
17.08.2018 | Materials Sciences